Automated minimal residual disease assessment in childhood acute myeloid leukemia
Acute leukemia is the most frequent cancer in children and adolescents. Assessment of the treatment response via quantification of minimal residual disease (MRD) at certain time-points of treatment has become a fundamental diagnostic procedure for tailoring therapy intensity and duration. In particular, children with the aggressive leukemia subtype of myeloid origin still face a need for highly toxic therapies due to a high relapse-propensity. Hence, there is a significant need for treatment improvement, which could be attained through better follow-up diagnostics using quality-assured MRD-assessment. Based on our recent achievements in the field of automated MRD quantification in pediatric acute lymphocytic leukemia (ALL), MyeFLOW now aims to use and further develop the latest algorithms for children with AML and to prepare the software for in vitro diagnostics (IVD) approval for fully automated, quality-assured evaluation of the treatment response in individual AML patients.
Labdia Labordiagnostik GmbH